Engineering a medical device for intranasal immunisation: ensuring targeted delivery and formulation stability
Abstract
Introduction The efficacy of nasal vaccination critically depends on the delivery method, which must ensure precise and reproducible deposition of the vaccine within the nasal cavity to effectively stimulate mucosal immune structures such as the nasal\x{2011}associated lymphoid tissue (NALT). Transitioning from pre\x{2011}clinical models to human applications is challenging because of anatomical and physiological differences in nasal structure and airflow dynamics. Methods We developed a nasal\x{2011}spray device specifically designed for human nasal immunization. The device delivers a broad, homogeneous spray that is confined to the nasal cavity, thereby avoiding the lower respiratory tract and minimizing the risk of pulmonary exposure. It was engineered to be compatible with a wide range of vaccine formulations, preserving their physicochemical properties, stability, and delivery efficacy. To overcome the limitations of conventional rodent models, the device was validated using (i) in\x{2011}vitro human nasal cavity replicas (nasal casts) and (ii) an in\x{2011}vivo rabbit model, which is more appropriate for regulatory and translational studies. Results The spray system achieved consistent, homogeneous deposition throughout the nasal cavity without spill\x{2011}over into the lower airways. Compatibility tests confirmed that the device does not alter the physicochemical characteristics or stability of a representative complex vaccine formulation. Validation in nasal casts and the rabbit model demonstrated reproducible delivery performance and supported the device\x{2019}s suitability for human use. Discussion The presented transitory delivery platform offers a scalable, safe, and formulation\x{2011}compatible solution for intranasal vaccine administration. By ensuring targeted deposition and preserving vaccine integrity, the device reinforces the potential of mucosal immunization strategies across diverse indications and facilitates the translation of nasal vaccines from pre\x{2011}clinical research to clinical application.
Related
- Intranasal hydrogels for Alzheimer’s disease: from nasal-interface engineering to brain targeting and translational readiness
- Evaluation of Antimicrobial Activity, Toxicity, and Stability of Andrographis paniculata Intimate Wash Formulation.
- Influence of Lipid Thioether Modification and Formulation Method on Lipoplex Structure, Stability and Transfection Efficiency in HEK293T Cells
- Ethosomal Nanocarriers for Trans-Resveratrol Delivery: Formulation, Physicochemical Characterization, Stability, and In Vitro Release Performance.
- Contextual factors shaping the delivery of routine immunisation services in the Mumbunda Health Zone, Democratic Republic of the Congo: a multiple case study of head nurses' experiences
BibTeX
@article{farias2026engineering,
title = {{Engineering a medical device for intranasal immunisation: ensuring targeted delivery and formulation stability}},
author = {Gonçalo Farias and Arnaud Bude and Nektaria Karavas and Christelle Rossignol and Isabelle Lantier and Julie Suman and Nicolas Aubrey and Isabelle Dimier-Poisson and Mathieu Epardaud},
journal = {Frontiers in Drug Delivery},
year = {2026},
month = aug,
doi = {10.3389/fddev.2026.1875011},
url = {https://hal.inrae.fr/hal-05759157v1},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Engineering a medical device for intranasal immunisation: ensuring targeted delivery and formulation stability
AU - Gonçalo Farias
AU - Arnaud Bude
AU - Nektaria Karavas
AU - Christelle Rossignol
AU - Isabelle Lantier
AU - Julie Suman
AU - Nicolas Aubrey
AU - Isabelle Dimier-Poisson
AU - Mathieu Epardaud
PY - 2026
DA - 2026/08/18
JO - Frontiers in Drug Delivery
DO - 10.3389/fddev.2026.1875011
UR - https://hal.inrae.fr/hal-05759157v1
AB - Introduction The efficacy of nasal vaccination critically depends on the delivery method, which must ensure precise and reproducible deposition of the vaccine within the nasal cavity to effectively stimulate mucosal immune structures such as the nasal\x{2011}associated lymphoid tissue (NALT). Transitioning from pre\x{2011}clinical models to human applications is challenging because of anatomical and physiological differences in nasal structure and airflow dynamics. Methods We developed a nasal\x{2011}spray device specifically designed for human nasal immunization. The device delivers a broad, homogeneous spray that is confined to the nasal cavity, thereby avoiding the lower respiratory tract and minimizing the risk of pulmonary exposure. It was engineered to be compatible with a wide range of vaccine formulations, preserving their physicochemical properties, stability, and delivery efficacy. To overcome the limitations of conventional rodent models, the device was validated using (i) in\x{2011}vitro human nasal cavity replicas (nasal casts) and (ii) an in\x{2011}vivo rabbit model, which is more appropriate for regulatory and translational studies. Results The spray system achieved consistent, homogeneous deposition throughout the nasal cavity without spill\x{2011}over into the lower airways. Compatibility tests confirmed that the device does not alter the physicochemical characteristics or stability of a representative complex vaccine formulation. Validation in nasal casts and the rabbit model demonstrated reproducible delivery performance and supported the device\x{2019}s suitability for human use. Discussion The presented transitory delivery platform offers a scalable, safe, and formulation\x{2011}compatible solution for intranasal vaccine administration. By ensuring targeted deposition and preserving vaccine integrity, the device reinforces the potential of mucosal immunization strategies across diverse indications and facilitates the translation of nasal vaccines from pre\x{2011}clinical research to clinical application.
SN - 2674-0850
SN - 2674-0850
ER -